[Prognosis estimation score in advanced ovarian cancer].
The retrospective analysis of 68 advanced ovarian cancer cases was performed mainly to see whether certain predictive factors were present which might distinguish patients with risk for recurrence or death from those with a good prognosis. Six factors, such as the mode of operation, the site of metastasis, the degree of peritonitis carcinomatosa, the rate of the decline in serum CA125. Performance Status, and pathological type were selected as factors influencing prognosis. We then tried to tally the prognosis estimation score using these factors. The correlation between this score and the survival period was noted in only patients with a survival time up to 3 years. The following formula was obtained: Y = 1.286X -3.429 [X: prognosis estimation score, Y: survival period (months)]. Cases were classified as follows according to the this score. When patients had a value equal to or less than 17.84.2% of patients died within 21 months, while if patients had a value greater than 17.34.7% of cases survived more than 36 months. On the other hand, 89.5% of cases with a survival period longer than 36 months had a prognosis estimation score greater than 18. However, there was little significant correlation between this score and the survival period in patients with survival period longer than 3 years. To conclude, although a low value for this score in advanced ovarian cancer, indicates a poorer prognosis, we cannot make an accurate prognosis for more than 3 years from this score.
Kobayashi
H
H
Department of Obstetrics and Gynecology, Hamamatsu University School of Medicine.
Kawashima
Y
Y
D000328:Adult; D000367:Age Factors; D000368:Aged; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000032:analysis; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D010052:Ovariectomy; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate
D015295:Antigens, Tumor-Associated, Carbohydrate; D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin